editor 
11:09 in the morning on April 26, 2024Freeslots777, Kailiying (06821)Freeslots777.HK) changes in stocksFreeslots777The share price soared by 5.00%. As of press time, the stock was reported at 61.951 Hong Kong dollars per share, with a turnover of 119660 shares, a turnover rate of 0.43% and an amplitude of 4.83%.
On the capital side, the stock has an inflow of HK $3.76906 million and an outflow of HK $2.89913 million.
Recent results showed that the stock had operating income of HK $8.587 billion, net profit of HK $2.504 billion, HK $6.91 per share and gross profit of HK $4.369 billion, a price-to-earnings ratio of 9.14 times.
In terms of institutional ratings, of all the 17 agencies that participated in the rating, 88% of the brokerages gave buy advice, 12% gave selling advice, and no brokerage gave holding advice.
In the pharmaceutical industry in which Kellein shares are located, the overall increase is 0.25%. Among its related stocks, Haiwang Interlon, Kanglong Huacheng and Kailiying rose significantly, while the related stocks with larger amplitudes were Sanai Health Group, Development Pharmaceutical Industry-B, and Kanglong Huacheng, with amplitudes of 13.79%, 10.64% and 6.70%, respectively.
Kelleying company profile: development, production and sale of high-tech pharmaceutical raw materials and intermediates and biotechnology productsFreeslots777, preparation research and development, import and export of related equipment and accessories, wholesale and retail business (without stores), as well as the above-mentioned related technical consulting services and technology transfer.
At the news level, as of 11:09, Kelleying stock positive public opinion news accounted for 14.29%. "Kelleying has been rated as a buy by CIC Securities with a target price of 85.50 yuan in 6 months." the information is an important information that affects Kellein. The information is summarized as follows: on April 26, Kellein was rated as a buy by CIC Securities, and Kellein received 10 research papers in the past month. CIC Securities expects the company's net profit from 2024 to 2026 to be 1.265 billion yuan, 1.431 billion yuan and 1.63 billion yuan respectively, an increase of-44.3%, 13.2% and 13.9% respectively over the same period last year. It is estimated that the target price in 2024 will be 85.50 yuan per share for six months.
(the above content is Portfolio based on public information, intelligently generated by programs or algorithms, only as a reference for users to view the market, not as investment advice or transaction basis. The stock market is risky, please make a careful decision. )